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A B S T R A C T
Introduction: Fatty acid oxidation disorders (FAODs) are rare diseases caused by defects in mitochondrial fatty
acid oxidation (FAO) enzymes. While the eﬃcacy of bezaﬁbrate, a peroxisome proliferator-activated receptor
agonist, on the in vitro FAO capacity has been reported, the in vivo eﬃcacy remains controversial. Therefore, we
conducted a clinical trial of bezaﬁbrate in Japanese patients with FAODs.
Materials and methods: This trial was an open-label, non-randomized, and multicenter study of bezaﬁbrate
treatment in 6 patients with very long-chain acyl-CoA dehydrogenase (VLCAD) deﬁciency and 2 patients with
carnitine palmitoyltransferase-II (CPT-2) deﬁciency (median age, 8.2 years; ranging from 5.8 to 26.4 years).
Bezaﬁbrate was administered for 6months following a 6-month observation period. The primary endpoint was
the frequency of myopathic attacks, and the secondary endpoints were serum acylcarnitines (ACs, C14:1 or
C16+C18:1), creatine kinase (CK) levels, degree of muscle pain (VAS; visual analog scale) during myopathic
attacks, and quality of life (QOL; evaluated using validated questionnaires).
Results: The frequency of myopathic attacks after bezaﬁbrate administration decreased in 3 patients, increased
in 3, and did not change in 2. The CK, AC, and VAS values during attacks could be estimated in only three or four
patients, but a half of the patients did not experience attacks before or after treatment. Changes in CK, AC, and
VAS values varied across individuals. In contrast, three components of QOL, namely, physical functioning, role
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limitation due to physical problems (role physical), and social functioning, were signiﬁcantly elevated. No ad-
verse drug reactions were observed.
Conclusion: In this study, the frequency of myopathic attacks and CK, AC, and VAS values during the attacks
could not be evaluated due to several limitations, such as a small trial population. Our ﬁndings indicate that
bezaﬁbrate improves the QOL of patients with FAODs, but its eﬃcacy must be examined in future investigations.
1. Introduction
Mitochondrial fatty acid oxidation disorders (FAODs) are caused by
defects in mitochondrial enzymes involved in fatty acid β-oxidation
(FAO), which play an important role in energy production during per-
iods when energy production from carbohydrates is reduced [1]. FAO
enzymes include very long-, medium-, and short-chain acyl-CoA dehy-
drogenases (VLCAD, MCAD, and SCAD, respectively), trifunctional
protein (TFP), carnitine-acylcarnitine translocase (CACT), carnitine
palmitoyltransferase-II (CPT-2), electron transfer ﬂavoprotein, and
electron transfer ﬂavoprotein dehydrogenase. Patients with FAODs
exhibit various symptoms triggered by infection, diarrhea, long fasting,
or muscular exertion [2]. FAODs are clinically classiﬁed into 3 types:
(1) neonatal onset type, which develops during the neonatal period or
early infancy with profound hypoglycemia, hepatic dysfunction, or
cardiac failure and is often fatal; (2) infantile onset type (intermediate
type), which exhibits intermittent attacks of lethargy, hepatic dys-
function, hypoglycemia, and occasionally encephalopathy or even
sudden infant death; and (3) adult onset myopathic type, which in-
volves episodic attacks of muscle weakness, myalgia, myoglobinuria, or
rhabdomyolysis after school age [3]. Although no drug treatments are
currently available for FAODs, avoiding long fasting, minimizing ex-
ercise, maintaining a low fat and high carbohydrate diet, and using
medium-chain triglyceride oil for long-chain FAODs in the stable con-
dition are used for prophylaxis against metabolic attacks. Further, early
glucose infusion is recommended in acute phases such as pyrexia,
diarrhea, or lethargy [4].
Bezaﬁbrate [2-(p-(2-(p-chlorobenzamido)ethyl)-phenoxy)-2-methyl
propionic acid] is a peroxisome proliferator-activated receptor (PPAR)
agonist [5] that decreases human serum lipid levels [6,7]. Recent re-
ports demonstrated that bezaﬁbrate may represent a promising drug for
FAODs by enhancing the transcription of several β-oxidation enzymes
in vitro [8–11]. Moreover, the clinical eﬃcacy of bezaﬁbrate for CPT-2
or multiple acyl-CoA dehydrogenase (MAD) deﬁciencies was recently
reported by French and Japanese groups, respectively [12–14]. Con-
versely, a 3-month, randomized, double-blind, crossover study invol-
ving a bezaﬁbrate clinical trial in patients with CPT-2 and VLCAD de-
ﬁciencies failed to demonstrate improvement in clinical symptoms or in
some physical abilities [15]. Hence, the clinical eﬃcacy of bezaﬁbrate
for FAODs is still controversial [16–18].
In this study, we evaluated the eﬃcacy and safety of bezaﬁbrate for
treating patients with FAODs by a clinical trial resembling the study
design of a previously reported French clinical trial [12].
2. Materials and methods
2.1. Design
This study was a non-randomized, uncontrolled multicenter, open-
label trial.
2.2. Standard protocol approvals, registrations, and patient consents
This study was approved by the Institutional Review Boards (IRBs)
Table 1
Clinical features and genotypes of the patients before enrollment.
VLCADD-1 VLCADD-2 VLCADD-3 VLCADD-4 VLCADD-5 VLCADD-6 CPT2D-1 CPT2D-2
Age 26 y 7 y 25 y 6 y 6 y 22 y 9 y 5 y
Sex F F M F M F F F
Diagnosis VLCADD VLCADD VLCADD VLCADD VLCADD VLCADD CPT-2D CPT-2D
Mutation F113* A333fs Untested R229X L243F E285G R51G F383Y
K382Q R450H Untested K382Q V547M V400M E174K R477W
Onset age 1.5 y 4.11 y 5 mo Around 1 y 3 y Around 13 y 1.3 y 3.7 y
Diagnosis age 5 y 5 y 13 y 0 mo 3 y 22 y 3 y 8 mo
Body weight (kg) 56 24 58 20 21 47 35 17
Clinical features Myalgia or
fatigue
Myalgia Myalgia or
fatigue
Myalgia or fatigue Myalgia or
rhabdomyolysis
Myalgia or
rhabdomyolysis
Myalgia Rhabdomyolysis or
hyper CK
Frequency of
Severe attacks 20/year 3/year 0 Several times/year 1–2/year 5/year Several times/
year
1/year
Moderate attacks 50–60/year 4/year 0 12/year 0 7/year Uncountable 0
Mild attacks Almost every day 6/year 2/year Uncountable 0 12/year Uncountable 0
Treatments
Carnitine (mg/
day)
750mg None 400–600mg almost none None 1800mg 1000mg 900–1800mg
MCT oil/milk None None Yes None Yes None Yes None
Restriction of
activity
Prolonged walk
and standing
PE, exercise,
and excursion
Airing Unclear None None None None
Responsiveness of
bezaﬁbrate in
vitro
Good Good Untested Good Good Good Good Untested
CK baseline (IU/L) 1933 ± 1220 180 ± 104 768 ± 612 1112 ± 1253 81 ± 13 590 ± 660 1201 ± 20 308 ± 169
C14:1 baseline (μM) 10.41 ± 4.64 1.18 ± 0.60 3.27 ± 4.05 2.98 ± 0.88 1.37 ± 1.77 1.36 ± 0.85
C16+C18:1
baseline (μM)
8.52 ± 5.40 6.94 ± 5.70
y, year; mo, month; M, male; F, female; VLCADD, very long-chain acyl-CoA dehydrogenase deﬁciency; CPT-2D, carnitine palmitoyltransferase-2 deﬁciency; PE, physical education.
Frequency of attacks and treatments were provided in the year prior to enrolment. Responsiveness of bezaﬁbrate in vitro was evaluated using the in vitro probe acylcarnitine assay [8].
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of Hokkaido University Hospital and the other collaborating institu-
tions. All patients were registered based on the database in the
Department of Pediatrics, Shimane University Faculty of Medicine.
Written informed consent for study participation was obtained from all
patients or their parents.
2.3. Setting
The study was conducted at Hokkaido University Hospital Clinical
Research and Medical Innovation Center, Japan, and the bezaﬁbrate
clinical trial was performed at each collaborating institution. The study
participants were recruited from January 2014 to December 2015.
Bezaﬁbrate was purchased from Kissei Pharmaceutical Co., Ltd.,
Nagano, Japan.
2.4. Patients
We originally recruited patients with CPT-2, VLCAD, TFP, MAD, and
CACT deﬁciencies whose diagnoses were genetically or en-
zymologically conﬁrmed. The target patient age was from 3 to 60 years
old. Patients with renal disorder (creatinine> 1.5mg/dL), with liver or
heart failure requiring medication, with a gallstone, or taking hydro-
xymethylglutaryl-CoA reductase inhibitor (hypolipidemic drug) and
female patients who were pregnant or expecting pregnancy were ex-
cluded from the study. Patients who manifested episodic attacks with
myopathic symptoms, such as general fatigue, severe myalgia, muscular
weakness, or myoglobinuria twice or more for six months, or those with
such episodes 4 times or more in a year and had high creatine kinase
(CK) (over two-fold elevation of normal range) during episodes of
myopathic symptoms were enrolled in this study. Ultimately, 8 patients
(6 with VLCAD and 2 with CPT-2 deﬁciencies) were registered from
February 2014 to May 2015. Clinical data of the 8 patients are shown in
Table 1.
Patient 1 (VLCADD-1) had a VLCAD deﬁciency and was a twenty-
six-year-old female who developed tachypnea and metabolic acidosis
soon after birth. At 1.5 years of age, she had an episode of vomiting,
syncope, and seizure accompanied by an increased blood CK level and
non-ketotic dicarboxylic aciduria following an infection. Thereafter, she
frequently suﬀered from vomiting and elevated CK levels during in-
fectious diseases. She was diagnosed with VLCAD deﬁciency at 5 years
old by enzyme analysis using ﬁbroblasts. Gene analysis identiﬁed mu-
tations of p.F113*/p.K382Q in ACADVL. She suﬀered from either
myalgia or general fatigue almost every day, which sometimes lead to
hospitalization due to the inability to move, before the enrollment of
this study.
VLCADD-2 was a seven-year-old girl who was diagnosed with
VLCAD deﬁciency when she developed rhabdomyolysis associated with
acute enteritis at 5 years old. She had compound heterozygous muta-
tions of p.A333fs/p.R450H in ACADVL. She exhibited gait diﬃculty due
to myalgia once or twice a month after diagnosis and presented with
occasional high CK levels (over 10,000 IU/L) or mild liver dysfunction
even in asymptomatic periods.
VLCADD-3 was a twenty-ﬁve-year old male. Although he exhibited
hypoglycemia, seizure, and fatty liver at 5months of age, he could not
be diagnosed. He was hospitalized due to a high CK level triggered by
an asthma attack at 5 years old, and at 12 years old, he frequently ex-
hibited general fatigue or an elevated CK level. He was diagnosed with
VLCAD deﬁciency based on the results of blood acylcarnitine (AC)
analysis and an in vitro probe assay [19]. He was aware of mild myalgia
and fatigue several times a month but lived normally, even with high
CK levels, into adulthood.
VLCADD-4 was a six-year-old girl diagnosed with VLCAD deﬁciency
by familial screening soon after birth because her mother was also af-
fected with VLCAD deﬁciency, and her father was a heterozygous car-
rier. She had compound heterozygous mutations of p.R229*/p.K382Q
in ACADVL. Although she was temporarily asymptomatic after diag-
nosis, she had been hospitalized for myalgia and fatigue two or three
times a year since her ﬁrst birthday. When she became more active in
nursery school, her myopathic symptoms occurred more frequently.
However, the frequency of her myopathic attacks was unknown. As her
mother was well aware of the symptoms of VLCAD deﬁciency, the pa-
tient was monitored at home during muscle symptom episodes.
Fig. 1. Study protocol.
If patients were classiﬁed as having a severe clinical disease course such as continued frequent myopathic attacks at the 38th week (12 weeks after starting standard treatment), then
enhanced-dose bezaﬁbrate was permissible.
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VLCADD-5 was a six-year-old boy who was diagnosed with VLCAD
deﬁciency at 3 years of age. His initial symptoms were hypoglycemia,
seizure, and high CK levels. Genetic analysis showed compound het-
erozygous mutations of p.L243F/p.V547M in ACADVL. He suﬀered
recurring bouts of rhabdomyolysis approximately once a month during
L-carnitine treatment. However, his attacks almost disappeared after
ceasing L-carnitine supplementation.
VLCADD-6 was a 22-year-old female. Since she was a junior high
school student, myalgia or muscle weakness occurred several times a
year after athletic festivals or climbing mountains. At 22 years old, she
was hospitalized due to manifestations of rhabdomyolysis such as
myoglobinuria and a high CK level (> 100,000 IU/L) and was conse-
quently diagnosed with VLCAD deﬁciency by muscle biopsy and
Western blot analysis, which identiﬁed p.E285G/p.V400M mutations.
Although she received lifestyle guidance such as frequent intake of oral
supplementation, her bouts of rhabdomyolysis occasionally recurred
even following mild exercise [20].
CPT2D-1 was a nine-year-old girl with CPT-2 deﬁciency. Her
younger brother also had CPT-2 deﬁciency (but was not enrolled in this
study). She was hospitalized due to unconsciousness and convulsion at
15months of age. She was suspected to have Reye-like syndrome ac-
companied by hypoglycemia and liver dysfunction. Since analyses of
her blood AC and urinary organic acid showed elevations in long-chain
ACs (particularly, C16 and C18:1) and hypoketotic dicarboxylic acid-
uria, respectively, CPT-2 or CACT deﬁciency was strongly suspected.
Subsequently, her diagnosis of CPT-2 deﬁciency was conﬁrmed by en-
zyme assay using ﬁbroblasts. Genetic testing showed compound het-
erozygous mutations of p.R51G/p.E174K in CPT2. Before enrollment in
this study, she occasionally suﬀered from myalgia triggered by fever or
exercise. However, because she did not visit a hospital after experien-
cing muscle symptoms, it was not possible to accurately assess the
frequency of her myopathic attacks.
CPT2D-2 was a ﬁve-year-old girl who was suspected of having CPT-
2 deﬁciency by a pilot study of expanded newborn screening. Her di-
agnosis was conﬁrmed by genetic analysis showing compound hetero-
zygous mutations of p.F383Y/p.R477W at 8months of age. Although
she experienced normal development in infancy, her ﬁrst metabolic
attack of rhabdomyolysis with elevated CK levels (50,999 IU/L) oc-
curred at 3 years and 7months old. Thereafter, she suﬀered repeated
bouts of rhabdomyolysis approximately twice a year following hy-
perpyrexia or exercise. However, she did not complain of muscle pain
during the episodes.
2.5. Protocol
As shown in Fig. 1, this study was composed of 3 periods: 1) a
screening period for 4 weeks; 2) an observation period for 24 weeks;
and 3) an administration period for 26 weeks. The administration
period was divided into a 2-week introductory period and a 24-week
standard treatment period. During the screening period, serum levels of
ACs and CK were measured three times over a 3-day interval during
asymptomatic conditions. Average AC and CK levels were provided as a
baseline that was used to determine the eﬃcacy of bezaﬁbrate and
whether participants were experiencing a myopathic attack. Further-
more, each patient's quality of life (QOL) was also analyzed using a 36-
Item Short Form Health Survey (SF-36) [21] during the same period.
The observation period immediately followed determination of baseline
AC and CK levels, irrespective of the screening period time-frame.
During the 24-week observation period, the frequency of myopathic
attacks, serum CK and AC levels and degree of myalgia using a visual
analog scale (VAS) during the metabolic attacks were investigated. The
elevation of VAS score implicated pain aggravation. After the ob-
servation period, low-dose bezaﬁbrate was administered for 2 weeks
during the introductory period. Bezaﬁbrate eﬃcacy was not in-
vestigated during this period. The bezaﬁbrate was administered as ta-
blets regardless of patient age because the tablets use a slow-release
system.
The dose of bezaﬁbrate was determined based on age (100, 200, and
400mg/day for patients aged 3–7.5, 7.5–12, and> 12 years, respec-
tively). Subsequently, treatment with standard-dose bezaﬁbrate (200,
300, and 600mg/day for patients aged 3–7.5, 7.5–12, and>12 years,
respectively) was initiated and continued for 24 weeks. If standard-dose
bezaﬁbrate did not reduce the frequency of myopathic attacks by the
12th week of treatment, then an enhanced treatment period of high-
dose bezaﬁbrate (300, 400, and 800mg/day for patients aged 3–7.5,
7.5–12, and>12 years, respectively) could be selected from the 12th to
24th week. The frequency of myopathic attacks and associated serum
levels of CK and AC were investigated during the standard or enhanced
treatment period as well as during the observation period. Patient QOL
was re-evaluated at the end of the administration period using the SF-
36. The drug compliance was calculated as (prescription number – re-
mainder number)/prescription number. There were regular blood ex-
aminations and laboratory data such as cholesterol and transaminase
levels collected once every two to four weeks during the treatment
period to monitor adverse eﬀects. CK and AC levels were not examined
in routine assessments.
2.6. Endpoint
We compared the frequency of myopathic attacks before and after
bezaﬁbrate treatment as a primary endpoint. A myopathic attack was
deﬁned as clinical features with a moderate or greater degree of muscle
symptoms such as general or extremity fatigue, muscle stiﬀness or
weakness, myalgia, or myoglobinuria that accompanied an elevated CK
level. In infants, poor activity and ill temper were considered myo-
pathic symptoms. An elevated CK level was deﬁned as a>5-fold in-
crease over baseline. While a moderate degree of muscle symptoms
indicated that patients experienced diﬃculties in performing routine
functions such as eating, dressing, toilet activity, and bathing due to
muscle symptoms, a severe degree demonstrated that patients could not
perform routine functions at all. A mild degree of muscle symptoms was
deﬁned as being able to perform routine activity despite myalgia and
fatigue and was not considered a myopathic attack.
Secondary endpoints were changes in CK, AC, and VAS values
during the myopathic attacks and QOL before and after bezaﬁbrate
treatment. Serum AC levels speciﬁc to each FAOD, for example, C14:1
in VLCAD deﬁciency and C16+C18:1 in CPT-2 deﬁciency, were in-
vestigated. The VAS represented the degree of myalgia based on a pain
scale of 0 to 100. QOL was quantitated using the SF-36 questionnaire,
which consisted of eight components such as physical functioning (PF),
role limitation due to physical problems (role physical; RP), bodily pain
(BP), general health perception (GHP), vitality (VT), social functioning
(SF), role limitation due to emotional problems (role emotional; RE),
and mental health (MH).
2.7. Data statistics and analysis
Although registration of approximately 58 patients was necessary to
obtain 80% statistical power to detect a diﬀerence between before (the
null average frequency of myopathic attacks= 3 per 24 weeks [12])
and after bezaﬁbrate treatment (the expected average frequency of
myopathic attacks= 2 per 24 weeks) based on a Poisson distribution
with two-sided α of 5%, only eight patients could participate in our
study. Therefore, we simply compared changes in individual endpoints
before and after bezaﬁbrate treatment. Only QOL data were analyzed
using a paired t-test for comparisons of the two periods using SAS
version 9.4 (SAS Institute Inc., Cary, NC, USA). Data were expressed as
the mean ± standard deviation, or median (minimum to maximum) as
appropriate.
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3. Results
All patients (6 with VLCAD and 2 with CPT-2 deﬁciencies), in-
cluding 2 males and 6 females, completed this study. There were no
dropouts. The median age was 6.9 (5.8 to 26.4) years. Age brackets
were assigned, and four patients were aged 3–7.5 years old, one was
7.5–12 years old, and the remaining 3 were>12 years old. Only
CPT2D-1 was treated with enhanced-dose bezaﬁbrate. Because the
metabolic attacks of CPT2D-1 were increased after bezaﬁbrate treat-
ment, 400mg of bezaﬁbrate, which was an enhanced dose for patients
aged 7.5–12 years, was administered to CPT2D-1 at the 38th week for
12 weeks following the standard treatment. Adverse drug reactions
were not observed in any cases during the administration period. All
patients strictly complied with this protocol, namely by immediately
visiting a hospital in the event of metabolic attack or maintaining a
consistent lifestyle before and after treatment, except for CPT2D-1, who
joined a school athletic festival during the administration period. All
patients had> 80% of drug compliance (range 83.1 to 100%, median
98.0%).
3.1. Primary endpoint
The number of myopathic attacks decreased in three patients
(VLCADD-2, VLCADD-4, and VLCADD-6), increased in three patients
(VLCADD-1, CPT2D-1, and VLCADD-5), and did not change in two
patients (VLCADD-3 and CPT2D-2) (Table 2). In the group with de-
creased attacks, VLCADD-4 and VLCADD-6 had no myopathic attacks
during the administration period, although they had attacks twice
during the observation period. The number of myopathic attacks for
VLCADD-2 decreased from 5 times before treatment to 4 times after
treatment. The number of myopathic attacks for VLCADD-1, VLCADD-5
and CPT2D-1 increased from 4 to 5, 1 to 2, and 1 to 4, respectively.
Although CPT2D-1 was treated with enhanced-dose bezaﬁbrate starting
at the 38th week, the frequency of his myopathic episodes did not de-
crease during the enhanced treatment period. VLCADD-3 and CPT2D-2
had no attacks before or after bezaﬁbrate treatment.
We evaluated the extent of myopathic symptoms. All myopathic
attacks were considered to be of a moderate degree before and after
treatment, except for CPT2D-1. CPTD-1 demonstrated severe myopathic
symptoms during both the observation and treatment periods, which
indicated that the degree of myopathic symptoms remained unchanged
after the treatment.
3.2. Secondary endpoints
3.2.1. Serum CK level during myopathic attacks
The average CK level during attacks decreased in two patients
(VLCADD-1 and CPT2D-1), increased in two (VLCADD-2 and VLCADD-
5) and was not evaluated in 4 (VLCADD-3, VLCADD-4, VLCADD-6, and
CPT2D-2) (Table 3). The number of VLCADD-1’s attacks increased from
4 to 5 during the treatment period, and the average CK level during
attacks marginally decreased from 23,905 to 23,235 IU/L; however,
overall CK levels during each attack largely varied (Table 8). Although
the number of attacks increased from 1 to 4 times in CPT2D-1, the
average CK level was reduced from 23,403 to 1269 IU/L. In contrast,
despite this reduction in the number of attacks, the average CK level
increased from 8714 to 9599 IU/L in VLCADD-2. Additionally, in
VLCADD-5, the frequency of attacks increased, and the average CK level
was elevated from 594 to 2783 IU/L after bezaﬁbrate treatment.
Changes in the CK level during attacks in the other 4 patients (VLCADD-
3, VLCADD-4, VLCADD-6, and CPT2D-2) were indeterminable because
they did not experience any attacks before or after treatment. The se-
verity of myopathic symptoms was not correlated with CK levels
(Table 8). During the severe attacks the CK levels were 23,403 IU/L
before the treatment and 1248 IU/L after treatment in CPT2D-1.
3.2.2. AC levels during myopathic attacks
In VLCAD deﬁciency, the C14:1 level during myopathic attacks in-
creased in two patients (VLCADD-1 and VLCADD-2) after treatment,
whereas this level was reduced in VLCADD-5. Conversely, C16+C18:1
was reduced in CPT2D-1 (Table 4). Similar to the CK results, the
changes in AC levels during myopathic attacks before and after treat-
ment could not be investigated in 4 patients because they did not ex-
perience any attacks during the observation or administration periods.
Although both the frequency of myopathic attacks and the CK level
increased in VLCADD-5 during the administration period, his average
C14:1 level during myopathic attacks decreased from 7.06 to 6.275 μM.
In VLCADD-1, whose CK level was decreased, the average C14:1 level
increased from 3.85 to 6.392 μM, and the number of attacks also in-
creased after treatment. In VLCADD-2, the number of attacks was re-
duced, but the C14:1 level increased from 9.44 to 17.328 μM, which
coincided with a mild elevation in CK. In contrast, average
C16+C18:1 level in CPT2D-1 reduced from 38.39 to 7.73 μM with a
concomitant decrease in CK level despite the increased number of at-
tacks.
3.2.3. VAS during myopathic attacks
Diﬀerences between VAS scores before and after treatment could be
investigated in only three patients (VLCADD-1, VLCADD-2, and CPT2D-
1) because VAS was not assessed in VLCADD-5 during the observation
period, and myopathic attacks were not observed before or after be-
zaﬁbrate treatment in other cases. VAS scores increased in VLCADD-1
(64.5 to 77.0), whereas scores decreased in VLCADD-2 (49.4 to 34.5)
and CPT2D-1 (75.0 to 56.5) during the administration period (Table 5).
The elevated VAS score indicated pain aggravation.
3.2.4. QOL using the SF-36 questionnaire
The QOL questionnaire results were obtained at the end of screening
period (before treatment) and treatment period (after treatment). The
elevation of QOL score indicated improvement of QOL. All components
of QOL were evaluated except for GHP in VLCADD-1. The average total
QOL score was signiﬁcantly elevated from 351.6 ± 69.1 to
390.0 ± 58.7 after bezaﬁbrate treatment (P= 0.01) (Table 6). There
were no patients whose total QOL score decreased. All QOL components
were improved in VLCADD-2 and VLCADD-5, while several components
were improved in the other patients (Fig. 2).
When analyzing each QOL component, three components, PF, RP,
and SF, signiﬁcantly improved after treatment, such that the PF, RP,
and SF scores were elevated from 43.0 to 50.6 (P < 0.01), 38.7 to 44.9
(P= 0.02), and 44.1 to 50.6 (P= 0.03), respectively (Table 7). Scores
of the other ﬁve components were also elevated but not signiﬁcantly.
4. Discussion
Our study was an open-label prospective clinical trial of bezaﬁbrate
treatment in patients with VLCAD and CPT-2 deﬁciencies. Although our
data analysis involved simple comparisons and was not statistically
analyzed due to a small study population, the frequency of myopathic
attacks decreased in some patients after bezaﬁbrate treatment but
Table 2
Comparison of the number of myopathic attacks.
Before After
VLCADD-1 4 5
VLCADD-2 5 4
VLCADD-3 0 0
VLCADD-4 2 0
VLCADD-5 1 2
VLCADD-6 2 0
CPT2D-1 1 4
CPT2D-2 0 0
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increased in others. Similarly, CK, AC, and VAS values during attacks
varied between individuals. Because there were a few ﬂaws in our study
design, the eﬃcacy of bezaﬁbrate on the frequency of myopathic at-
tacks and CK, AC, and VAS values during attacks remained un-
determined. However, our results suggested that bezaﬁbrate improved
the QOL of patients with FAODs.
To investigate the frequency of myopathic attacks as a primary
endpoint, we attempted to recruit patients who continued to have in-
termittent metabolic attacks despite standard treatments such as diet
therapy and restriction of over exercise. However, only 8 patients
participated in this trial, which was less than originally expected and
insuﬃcient to perform statistical analyses, even if there was a clear
trend in some endpoints. Nevertheless, some QOL components were
signiﬁcantly improved despite the small study population. Additionally,
in vitro responsiveness to bezaﬁbrate was not measured in all partici-
pants, and this was one of major problems in our study. Although six
participants were responders in vitro, the number of attacks was not
decreased in VLCADD-1, VLCADD-5, and CPT2D-1. This diﬀerence
might be due to inadequate design of this study, and the in vitro re-
sponsiveness of all patients should have been inspected before enroll-
ment in the trial.
In our study, “myopathic attack” was deﬁned as a 5-fold increase
over baseline CK levels, which was ultimately one of the limitations of
this study. This cutoﬀ was derived from criteria of rhabdomyolysis in
which the CK level is elevated 5- to 10-fold higher than normal level
[22,23]. However, although the baseline level of CK was obtained in
“the asymptomatic condition”, it was higher than the CK level in the
“real” stable condition in some patients (data not shown). This com-
plicated obtaining data that met the deﬁnition of a myopathic attack.
Indeed, even though the patients visited the hospital with myalgia and
general fatigue, such episodes are sometimes not regarded as a ‘myo-
pathic attack’ due to insuﬃcient increases in the CK level. Therefore,
the frequency of myopathic attacks observed during the observation
and administration periods was lower than that before initiation of this
study. Moreover, such episodes might also be inﬂuenced by a time lag
in the elevation of serum CK levels [24]. The elevation of CK might be
delayed following the manifestation of patient symptoms such as
myalgia and fatigue. Therefore, it is likely that the number of attacks
and CK levels during attacks were underestimated. Although we re-
quested that all participants visited an attending physician as soon as
possible upon ﬁrst muscle symptoms, sampling time might be diﬀerent
for each individual due to various factors, such as distance to the hos-
pital. This also might have contributed to the variability of CK levels
and makes it diﬃcult to interpret our results. Furthermore, it is possible
that child patients tended to be more active after bezaﬁbrate adminis-
tration, since muscle weakness and myalgia became milder than before
administration. We requested all participants to keep their daily life and
activity consistent before and after the treatment. However, the patients
might have been more physically active, which was noted by the at-
tending physicians. This concept also may be one explanation for why
the number of myopathic attacks, CK, ACs, and VAS did not decrease
markedly. We could not validate the extent of the change in physical
activity of the patients because this was not a study endpoint. There-
fore, future studies should track physical activity using a diary because
it is more informative than biochemical markers in this kind of trial.
This study protocol determined CK, AC, and VAS values exclusively
at the time of myopathic attacks. As a result, we could not obtain
considerable quantities of data and ultimately excluded 4 patients.
There were two patients who did not experience attacks after bezaﬁ-
brate administration. This ﬁnding indicated that our results on the
changes in CK, AC, and VAS values during attacks did not reﬂect those 2
cases who were likely to be good responders to bezaﬁbrate treatment.
Additionally, the treatment period might have been too short to es-
tablish the eﬃcacy of bezaﬁbrate. We found that VLCADD-1 and
CPT2D-1, who were considered non-responders in this study, became
physically ﬁt when they continued with bezaﬁbrate therapy after our
study.
The QOL scores were collected using the SF-36 for all participants
regardless of the status of myopathic attacks. The three QOL compo-
nents of PF, RP, and SF were signiﬁcantly improved after bezaﬁbrate
treatment. The other ﬁve components also improved, but the changes
were not statistically signiﬁcant. Thus, it is diﬃcult to conclude that
bezaﬁbrate improved patient QOL only using these results. However,
we considered that it was very meaningful to have statistical sig-
niﬁcance for 3 of the 8 QOL components with our very small participant
population.
SF-36 has been used in various studies and is a reliable
Table 3
Comparison of the CK levels during myopathic attacks.
Before After (Diﬀerence)
VLCADD-1 23,905 ± 23,726 23,235 ± 11,505 (−670)
VLCADD-2 8714 ± 1578 9599 ± 7407 (885)
VLCADD-3 – –
VLCADD-4 8943 ± 2940 –
VLCADD-5 594 2783 ± 1559 (2189)
VLCADD-6 11,325 ± 11,418 –
CPT2D-1 23,403 1269 ± 313 (−22,134)
CPT2D-2 – –
Table 4
Comparison of the AC levels during myopathic attacks.
Before After (Diﬀerence)
C14:1 (μM)
VLCADD-1 3.85 ± 2.75 6.39 ± 6.96 (2.54)
VLCADD-2 9.44 ± 4.01 17.33 ± 2.89 (7.89)
VLCADD-3 – – –
VLCADD-4 7.26 ± 6.37 – –
VLCADD-5 7.06 6.28 ± 3.15 (−0.79)
VLCADD-6 0.570 ± 0.014 – –
C16+C18:1 (μM)
CPT2D-1 38.39 7.73 ± 2.51 (−30.67)
CPT2D-2 – – –
Table 5
Comparison of the VAS scores during myopathic attacks.
Before After (Diﬀerence)
VLCADD-1 64.5 ± 15.0 77.0 ± 1.9 (12.5)
VLCADD-2 49.4 ± 11.7 34.5 ± 17.7 (−14.9)
VLCADD-3 – – –
VLCADD-4 43.5 ± 2.1 – –
VLCADD-5 – 64.5 ± 21.9 –
VLCADD-6 48.0 ± 39.6 – –
CPT2D-1 75.0 56.5 ± 27.0 (−18.5)
CPT2D-2 – – –
Elevation of VAS score indicates pain aggravation.
Table 6
Comparison of the total QOL scores using the SF-36 before and after treatment.
Before After (Diﬀerence)
VLCADD-1 247.4 267.8 (20.4)
VLCADD-2 313.5 408.4 (94.9)
VLCADD-3 392 423.4 (31.4)
VLCADD-4 381.3 415.5 (34.2)
VLCADD-5 271.5 353.5 (82)
VLCADD-6 371 385.8 (14.8)
CPT2D-1 379.7 400.2 (20.5)
CPT2D-2 456.7 465.2 (8.5)
Average 351.6 390.0 P= .01
Elevation of QOL score indicates improvement of QOL.
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questionnaire that evaluates both physical and mental functions
[21,25,26]. Bonnefont et al. previously reported that SF-36 values of
patients with CPT-2 deﬁciency improved after bezaﬁbrate treatment
[13]. Although our study and Bonnefont's report could be inﬂuenced by
a placebo eﬀect due to being an open-label study, myopathic symptoms
could not be objectively estimated even using the biomarkers CK and
AC. This is because the VAS, which quantiﬁes subjective pain, does not
correlate with the CK or AC levels, as shown in Table 8. Hence, al-
though estimating QOL using SF-36 was subjective and a secondary
endpoint, we believe that the QOL values are the most trustworthy
results in this study. Even in CPT2D-1 and VLCADD-5, who showed no
response to bezaﬁbrate treatment regarding the frequency of myopathic
attacks, almost all components of QOL were increased, suggesting that
bezaﬁbrate is eﬀective for improving QOL. Additionally, more than half
of the patients and attending physicians vaguely realized “some kind of
bezaﬁbrate eﬃcacy” even though the frequency of myopathic attacks,
degree of muscle symptoms, and biochemical markers such as CK levels
did not signiﬁcantly improve. If “some kind of eﬃcacy” can be correctly
investigated, bezaﬁbrate will be a promising drug for FAODs.
Lastly, we did not experience any bezaﬁbrate-related adverse events
or unexpected incidents during the entire period of this study, even
though our data contained a patient who received high dose of beza-
ﬁbrate (400mg/day for a 9-year-old patient). For decades, bezaﬁbrate
has been used to treat many patients with hyperlipidemia, and in this
study, we conﬁrmed its safety in patients with FAODs.
5. Conclusion
Our study failed to demonstrate the evident eﬃcacy of bezaﬁbrate
treatment on the frequency of myopathic attacks, CK and AC levels, or
VAS, but this study did not negate its eﬀectiveness either. However,
although bezaﬁbrate eﬃcacy remains controversial, our ﬁndings sup-
port one of its beneﬁts in improving the QOL of patients with FAODs.
Further studies with additional clinical trials are essential to elucidate
the eﬃcacy of bezaﬁbrate for patients with FAODs.
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Fig. 2. Quality of life evaluation in each patient.
White and gray bars indicate before and after the treatment, respectively.
PF, physical functioning; RP, role limitation due to physical problems; BP, bodily pain; GHP, general health perception; VT, vitality; SF, social functioning; RE, role limitation due to
emotional problems; MH, mental health.
Table 7
QOL results from the SF-36 administered before and after treatment.
Before After p value
Physical functioning (n= 8) 43.0 50.6 < 0.01
Role physical (n=8) 38.7 44.9 0.02
Bodily pain (n=8) 39.7 44.9 0.11
General health perceptions (n= 7) 46.1 48.0 0.36
Vitality (n= 8) 48.2 51.0 0.19
Social functioning (n= 8) 44.1 50.6 0.03
Role emotional (n=8) 45.1 48.8 0.32
Mental health (n= 8) 52.5 57.2 0.07
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